Tags

Type your tag names separated by a space and hit enter

Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Pediatr Infect Dis J. 2006 Apr; 25(4):287-92.PI

Abstract

BACKGROUND

A study was conducted to assess administration of a combination measles, mumps, rubella and varicella vaccine (MMRV) with other childhood vaccines.

METHODS

In this open, multicenter trial, 1915 healthy children ages 12-15 months were randomized into 3 groups: group 1, MMRV, combined Haemophilus influenzae type b conjugate-hepatitis B vaccines (Hib/HepB) and combined diphtheria-tetanus-acellular pertussis vaccines (DTaP) concomitantly; group 2, MMRV followed by Hib/HepB and DTaP 42 days later; group 3, MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later.

RESULTS

Antibody responses to measles, mumps, rubella, varicella, Hib, HepB, diphtheria and tetanus were similar between groups 1 and 2 (all >95%, except varicella, 89.7% in group 1 and 90.9% in group 2). Pertussis toxin and filamentous hemagglutinin responses were significantly lower in group 1 than in group 2 (group 1, 74.1 and 67.1%; group 2, 90.4 and 86.8%, respectively). An exploratory analysis suggested that the difference in and pertussis toxin and filamentous hemagglutinin responses was likely the result of study design rather than interference among vaccine components because the groups differed in age of receipt of DTaP (group 1, approximately 12 months; group 2, approximately 13.5 months). When the groups were matched for age, sample size was sufficient for comparison only in children > or =13.5 months old. Pertussis toxin and filamentous hemagglutinin responses were similar in these children. The safety profiles for each vaccination regimen were comparable.

CONCLUSIONS

The immunogenicity data support concomitant administration of MMRV with Hib/HepB. Limited data from an exploratory analysis indicate that MMRV can be administered concomitantly with DTaP. Concomitant administration of MMRV, Hib/HepB and DTaP is well-tolerated.

Authors+Show Affiliations

University of California School of Medicine, San Francisco, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16567978

Citation

Shinefield, Henry, et al. "Safety and Immunogenicity of a Measles, Mumps, Rubella and Varicella Vaccine Given With Combined Haemophilus Influenzae Type B Conjugate/hepatitis B Vaccines and Combined Diphtheria-tetanus-acellular Pertussis Vaccines." The Pediatric Infectious Disease Journal, vol. 25, no. 4, 2006, pp. 287-92.
Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006;25(4):287-92.
Shinefield, H., Black, S., Thear, M., Coury, D., Reisinger, K., Rothstein, E., Xu, J., Hartzel, J., Evans, B., Digilio, L., Schödel, F., Brown, M. L., & Kuter, B. (2006). Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. The Pediatric Infectious Disease Journal, 25(4), 287-92.
Shinefield H, et al. Safety and Immunogenicity of a Measles, Mumps, Rubella and Varicella Vaccine Given With Combined Haemophilus Influenzae Type B Conjugate/hepatitis B Vaccines and Combined Diphtheria-tetanus-acellular Pertussis Vaccines. Pediatr Infect Dis J. 2006;25(4):287-92. PubMed PMID: 16567978.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. AU - Shinefield,Henry, AU - Black,Steve, AU - Thear,Marci, AU - Coury,Daniel, AU - Reisinger,Keith, AU - Rothstein,Edward, AU - Xu,Jin, AU - Hartzel,Jonathan, AU - Evans,Barbara, AU - Digilio,Laura, AU - Schödel,Florian, AU - Brown,Michelle L Hoffman, AU - Kuter,Barbara, AU - ,, PY - 2006/3/29/pubmed PY - 2006/6/10/medline PY - 2006/3/29/entrez SP - 287 EP - 92 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 25 IS - 4 N2 - BACKGROUND: A study was conducted to assess administration of a combination measles, mumps, rubella and varicella vaccine (MMRV) with other childhood vaccines. METHODS: In this open, multicenter trial, 1915 healthy children ages 12-15 months were randomized into 3 groups: group 1, MMRV, combined Haemophilus influenzae type b conjugate-hepatitis B vaccines (Hib/HepB) and combined diphtheria-tetanus-acellular pertussis vaccines (DTaP) concomitantly; group 2, MMRV followed by Hib/HepB and DTaP 42 days later; group 3, MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later. RESULTS: Antibody responses to measles, mumps, rubella, varicella, Hib, HepB, diphtheria and tetanus were similar between groups 1 and 2 (all >95%, except varicella, 89.7% in group 1 and 90.9% in group 2). Pertussis toxin and filamentous hemagglutinin responses were significantly lower in group 1 than in group 2 (group 1, 74.1 and 67.1%; group 2, 90.4 and 86.8%, respectively). An exploratory analysis suggested that the difference in and pertussis toxin and filamentous hemagglutinin responses was likely the result of study design rather than interference among vaccine components because the groups differed in age of receipt of DTaP (group 1, approximately 12 months; group 2, approximately 13.5 months). When the groups were matched for age, sample size was sufficient for comparison only in children > or =13.5 months old. Pertussis toxin and filamentous hemagglutinin responses were similar in these children. The safety profiles for each vaccination regimen were comparable. CONCLUSIONS: The immunogenicity data support concomitant administration of MMRV with Hib/HepB. Limited data from an exploratory analysis indicate that MMRV can be administered concomitantly with DTaP. Concomitant administration of MMRV, Hib/HepB and DTaP is well-tolerated. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/16567978/Safety_and_immunogenicity_of_a_measles_mumps_rubella_and_varicella_vaccine_given_with_combined_Haemophilus_influenzae_type_b_conjugate/hepatitis_B_vaccines_and_combined_diphtheria_tetanus_acellular_pertussis_vaccines_ L2 - https://doi.org/10.1097/01.inf.0000207857.10947.1f DB - PRIME DP - Unbound Medicine ER -